These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18215088)

  • 1. Targeted immunotherapy for staphylococcal infections : focus on anti-MSCRAMM antibodies.
    Otto M
    BioDrugs; 2008; 22(1):27-36. PubMed ID: 18215088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MSCRAMM--targeted vaccines and immunotherapy for staphylococcal infection.
    Rivas JM; Speziale P; Patti JM; Höök M
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):223-7. PubMed ID: 15603256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic strategies to combat staphylococcal infections.
    Ohlsen K; Lorenz U
    Int J Med Microbiol; 2010 Aug; 300(6):402-10. PubMed ID: 20547101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein.
    Therrien R; Lacasse P; Grondin G; Talbot BG
    Vaccine; 2007 Jun; 25(27):5053-61. PubMed ID: 17532546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staphylococcal vaccines and immunotherapy: to dream the impossible dream?
    Projan SJ; Nesin M; Dunman PM
    Curr Opin Pharmacol; 2006 Oct; 6(5):473-9. PubMed ID: 16870507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic approaches against Staphylococcus aureus.
    Verkaik NJ; van Wamel WJ; van Belkum A
    Immunotherapy; 2011 Sep; 3(9):1063-73. PubMed ID: 21913829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant.
    Camussone CM; Pujato N; Renna MS; Veaute CM; Morein B; Marcipar IS; Calvinho LF
    Vet Immunol Immunopathol; 2014 Dec; 162(3-4):96-107. PubMed ID: 25454469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of a 4-Component Toxoid-Based
    Venkatasubramaniam A; Liao G; Cho E; Adhikari RP; Kort T; Holtsberg FW; Elsass KE; Kobs DJ; Rudge TL; Kauffman KD; Lora NE; Barber DL; Aman MJ; Karauzum H
    Front Immunol; 2021; 12():621754. PubMed ID: 33717122
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model.
    Schaffer AC; Solinga RM; Cocchiaro J; Portoles M; Kiser KB; Risley A; Randall SM; Valtulina V; Speziale P; Walsh E; Foster T; Lee JC
    Infect Immun; 2006 Apr; 74(4):2145-53. PubMed ID: 16552044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular-matrix-binding proteins as targets for the prevention of Staphylococcus aureus infections.
    Flock JI
    Mol Med Today; 1999 Dec; 5(12):532-7. PubMed ID: 10562719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-17A plays an important role in protection induced by vaccination with fibronectin-binding domain of fibronectin-binding protein A against Staphylococcus aureus infection.
    Narita K; Asano K; Nakane A
    Med Microbiol Immunol; 2017 Jun; 206(3):225-234. PubMed ID: 28378247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination and passive immunisation against Staphylococcus aureus.
    Schaffer AC; Lee JC
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S71-8. PubMed ID: 18757184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges for a universal Staphylococcus aureus vaccine.
    Proctor RA
    Clin Infect Dis; 2012 Apr; 54(8):1179-86. PubMed ID: 22354924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of repeated administration of staphylococcal immune preparations on the development of local staphylococcal infection in mice.
    Yegorova NB; Korzaya LI
    J Hyg Epidemiol Microbiol Immunol; 1983; 27(2):203-10. PubMed ID: 6684137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention and immunotherapy of staphylococcal infections with bacterial vaccines].
    Kuz'menko OM; Gruber IM; Priiatkin RG
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (5):106-12. PubMed ID: 21061586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targeted immunotherapy approaches for staphylococcal infection.
    Otto M
    Expert Opin Biol Ther; 2010 Jul; 10(7):1049-59. PubMed ID: 20528609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines and immunotherapy for staphylococcal infections.
    Patti JM
    Int J Artif Organs; 2005 Nov; 28(11):1157-62. PubMed ID: 16353122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide.
    Maira-Litran T; Kropec A; Goldmann D; Pier GB
    Vaccine; 2004 Feb; 22(7):872-9. PubMed ID: 15040940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a future for a Staphylococcus aureus vaccine?
    Proctor RA
    Vaccine; 2012 Apr; 30(19):2921-7. PubMed ID: 22115633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage.
    Botelho-Nevers E; Verhoeven P; Paul S; Grattard F; Pozzetto B; Berthelot P; Lucht F
    Expert Rev Vaccines; 2013 Nov; 12(11):1249-59. PubMed ID: 24111513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.